Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin‐B is not indicated.

中文翻译：

---

在西班牙进行病原体鉴别诊断之前，艾沙康唑与伏立康唑的成本效益相比，伏立康唑是侵袭性霉菌病患者的治疗标准

侵袭性霉菌病与高发病率、死亡率和经济影响有关。它的治疗通常在鉴别病原体诊断之前开始。艾沙康唑被批准用于治疗没有使用两性霉素 B 的侵袭性曲霉病 (IA) 和侵袭性毛霉菌病 (IM)。